Abstract
AbstractBackgroundHigh-dose quadrivalent influenza vaccine (HD-QIV) was introduced during the 2021/22 influenza season in France for adults aged ≥65 years as an alternative to standard-dose quadrivalent influenza vaccines (SD-QIV). This is the first study to estimate the relative vaccine effectiveness (rVE) of HD-QIV versus SD-QIV against influenza-related hospitalizations in France.MethodsCommunity-dwelling individuals aged ≥65 years with reimbursed influenza vaccine claims during the 2021/22 influenza season were included from the French national health insurance database. Individuals were followed up from vaccination day to 30 June 2022, nursing home admission or death date. Baseline socio-demographic and health characteristics were identified from medical records over the 5 previous years. Hospitalizations due to influenza and other causes were recorded from 14 days after vaccination to end of follow-up. HD-QIV and SD-QIV vaccinees were matched using 1:4 propensity score matching with an exact constraint on age group, sex, week of vaccination and region. Incidence rate ratios (IRR) were estimated using zero-inflated Poisson or zero-inflated negative binomial regression models.ResultsWe matched 405,385 (99.9%) HD-QIV to 1,621,540 SD-QIV vaccinees. HD-QIV was associated with a 23.3% (95%CI: 8.4–35.8) lower rate of influenza hospitalizations compared to SD-QIV. Post-matching, we observed higher rates in the HD-QIV group for hospitalizations non-specific to influenza and for negative control outcomes, suggesting residual confounding by indication.ConclusionsHD-QIV was associated with lower influenza-related hospitalization rates versus SD-QIV, consistent with existing evidence, in the context of high SARS-CoV-2 circulation in France and likely prioritization of HD-QIV for older/more comorbid individuals.
Publisher
Cold Spring Harbor Laboratory
Reference29 articles.
1. Recommandations SFGG vaccin haute dose Efluelda. 2021. Available from: https://sfgg.org/recommandations/anti-grippe-le-vaccin-haute-dose-efluelda/ (accessed 9 June 2023).
2. La grippe, une épidémie saisonnière. 2019. Available from: https://www.santepubliquefrance.fr/maladies-et-traumatismes/maladies-et-infections-respiratoires/grippe/articles/la-grippe-une-epidemie-saisonniere (accessed 9 June 2023).
3. Avis relatif à l’efficacité de la vaccination contre la grippe saisonnière notamment chez les personnes âgées et à la place de la vaccination des professionnels de santé dans la stratégie de prévention de la grippe, HSCP, 28 mars 2014. 2014. Available from: https://www.hcsp.fr/Explore.cgi/avisrapportsdomaine?clefr=424.
4. Immunosenescence and Its Hallmarks: How to Oppose Aging Strategically? A Review of Potential Options for Therapeutic Intervention;Front Immunol,2019
5. Efficacy of High-Dose versus Standard-Dose Influenza Vaccine in Older Adults